ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

CDXC ChromaDex Corporation

2.80
0.025 (0.90%)
Last Updated: 15:18:29
Delayed by 15 minutes
Share Name Share Symbol Market Type
ChromaDex Corporation NASDAQ:CDXC NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.025 0.90% 2.80 2.79 2.81 2.88 2.78 2.81 37,581 15:18:29

ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024

05/02/2024 1:32pm

Business Wire


ChromaDex (NASDAQ:CDXC)
Historical Stock Chart


From Jan 2024 to Jul 2024

Click Here for more ChromaDex Charts.

ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy aging research, announced today that it will be participating in Renmark Financial Communications Inc.’s live Virtual Non-Deal Roadshow Series to discuss its latest investor presentation on Monday, February 12, 2024, at 11:00 AM PST. ChromaDex welcomes stakeholders, investors, and other individual followers to register and attend this live event.

The presentation will feature ChromaDex’s Chief Executive Officer, Rob Fried, and Chief Financial Officer, Brianna Gerber. Topics to be covered will include the latest investor presentation followed by a live Q&A. Investors interested in participating in this event will need to register using the link below. As a reminder, registration for the live event may be limited but access to the replay after the event will be on the Investor Relations section of ChromaDex’s website, investors.chromadex.com.

REGISTER HERE:

Monday, February 12, 2024: https://www.renmarkfinancial.com/live-registration/renmark-virtual-non-deal-roadshow-nasdaq-cdxc-2024-02-12-110000

  • To ensure smooth connectivity, please access this link using the latest version of Google Chrome.

For additional information on ChromaDex, visit www.chromadex.com.

About ChromaDex:

ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

About Renmark Financial Communications Inc.

Founded in 1999, Renmark is a privately held full-service investor relations firm, located in Atlanta, New York, Toronto, and Montreal. For the past 25 years, Renmark has provided services in investor relations, media relations, and web development representing small, medium, and large-cap public companies listed on all major North American exchanges. On a daily basis, our team of professionals enhances our clients’ visibility within the retail market space as corporate communicators. With the largest roadshow footprint in North America and a state-of-the-art media studio, we host a multitude of live-streaming Virtual Non-Deal Roadshows across North America and Europe.

ChromaDex Media Contact: Kendall Knysch, Head of Media Relations & Partnerships 310-388-6706 ext. 689 kendall.knysch@chromadex.com

ChromaDex Investor Relations Contact: +1 (949) 356-1620 InvestorRelations@ChromaDex.com

1 Year ChromaDex Chart

1 Year ChromaDex Chart

1 Month ChromaDex Chart

1 Month ChromaDex Chart

Your Recent History

Delayed Upgrade Clock